These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 17895381)
1. Molecular basis for passive immunotherapy of Alzheimer's disease. Gardberg AS; Dice LT; Ou S; Rich RL; Helmbrecht E; Ko J; Wetzel R; Myszka DG; Patterson PH; Dealwis C Proc Natl Acad Sci U S A; 2007 Oct; 104(40):15659-64. PubMed ID: 17895381 [TBL] [Abstract][Full Text] [Related]
2. Structures of Abeta-related peptide--monoclonal antibody complexes. Gardberg A; Dice L; Pridgen K; Ko J; Patterson P; Ou S; Wetzel R; Dealwis C Biochemistry; 2009 Jun; 48(23):5210-7. PubMed ID: 19385664 [TBL] [Abstract][Full Text] [Related]
3. Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. van Dyck CH Biol Psychiatry; 2018 Feb; 83(4):311-319. PubMed ID: 28967385 [TBL] [Abstract][Full Text] [Related]
4. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease? Panza F; Logroscino G; Imbimbo BP; Solfrizzi V Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401 [TBL] [Abstract][Full Text] [Related]
11. Conformation-specific antibodies to target amyloid β oligomers and their application to immunotherapy for Alzheimer's disease. Murakami K Biosci Biotechnol Biochem; 2014; 78(8):1293-305. PubMed ID: 25130729 [TBL] [Abstract][Full Text] [Related]
15. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109 [TBL] [Abstract][Full Text] [Related]
16. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231 [TBL] [Abstract][Full Text] [Related]
17. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740 [TBL] [Abstract][Full Text] [Related]
18. Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides. Rossi M; Piovesan P; Ghirardi O; Mastroianni D; Bombardi V; Battistini L; Cencioni MT; Capobianco D; Borsini F; Colombo M; Verdoliva A Mol Immunol; 2009 Aug; 46(13):2524-32. PubMed ID: 19535144 [TBL] [Abstract][Full Text] [Related]
19. Molecular characterization of the β-amyloid(4-10) epitope of plaque specific Aβ antibodies by affinity-mass spectrometry using alanine site mutation. Ștefănescu R; Lupu L; Manea M; Iacob RE; Przybylski M J Pept Sci; 2018 Jan; 24(1):. PubMed ID: 29322650 [TBL] [Abstract][Full Text] [Related]
20. Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease. Söllvander S; Ekholm-Pettersson F; Brundin RM; Westman G; Kilander L; Paulie S; Lannfelt L; Sehlin D J Alzheimers Dis; 2015; 48(1):63-72. PubMed ID: 26401929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]